Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  08:46:17 2023-01-27 am EST
0.0294 CHF   -0.68%
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer Drug
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about RELIEF THERAPEUTICS HOLDING AG
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial E..
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer D..
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating R..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVAfor Pati..
AQ
2022Acer Therapeutics' Olpruva Approved by FDA, Triggers Availability of $42.5 Million Loan
MT
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
AQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ f..
CI
2022Relief Therapeutics, Acer Therapeutics Win US FDA Nod For Urea Cycle Disorders Treatmen..
MT
2022Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 wit..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
EQ
2022Acer Therapeutics Gets FDA Approval for Lead Drug Candidate Olpruva
DJ
2022Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definiti..
AQ
2022Relief Therapeutics, NRx Pharmaceuticals Settle Litigation for Aviptadil Development Pr..
MT
2022Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definiti..
EQ
2022Relief Therapeutics Holding AG (SWX:RLF) acquired ZY..
CI
2022Relief Therapeutics to Participate in January Investor Meetings
EQ
2022Swiss Biopharmaceutical Relief Therapeutics to Issue New Shares
MT
2022Relief Therapeutics Announces Issuance of Shares from Authorized Capital
EQ
2022Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer
CI
2022Relief Therapeutics Holding AG Appoints Jack Weinstein as Chief Executive Officer
CI
2022Relief Therapeutics Names New CEO, CFO
MT
2022Relief Therapeutics Announces Executive Leadership Team Changes
EQ
2022APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the ..
EQ
2022Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 wit..
EQ
2022Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
2022Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Defi..
EQ
2022An unknown buyer entered into a Asset Purchase Agreement to acquire ZYESAMI of NRx Phar..
CI
2022Relief Therapeutics, NRx Further Extend Stay of Pending Aviptadil Dispute
MT
2022Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay ..
EQ
2022Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation ..
CI
2022Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data
MT
2022Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 ..
EQ
2022Relief Therapeutics, NRx Extend Stay For Pending Aviptadil Dispute
MT
2022RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pendi..
EQ
2022Relief Therapeutics Seeks Reverse Split, Ratio Change Amid Move to NASDAQ
MT
2022Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with t..
EQ
2022RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer
CI
2022Relief Therapeutics Names New COO
MT
2022Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
EQ
2022Switzerland's Relief Therapeutics Rolls Out PKU GOLIKE in US
MT
2022Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE
CI
2022Relief Announces U.S. Launch of PKU GOLIKE
EQ
2022Relief Therapeutics Chooses Exclusive US Distributor For PKU GOLIKE
MT
2022Relief Therapeutics Holding Ag Announces Exclusive Distributor for Pku Golike in the U...
CI
2022Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
EQ
2022Relief Therapeutics Partner Acer To Secure US Patent For Phenylbutyrate-Sodium Benzoate..
MT
2022Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US..
EQ
2022Relief Therapeutics Gets US Approval to Launch Pilot Trial For Skin Disease Treatment
MT
2022Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator..
CI
2022Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated ..
EQ
2022Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30..
CI
2022Relief Therapeutics Posts Wider Attributable Loss In H1
MT
2022Relief Reports Half-Year 2022 Results and Provides Corporate Update
EQ
2022Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
EQ
2022Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment..
EQ
2022Switzerland's Relief Therapeutics Seeks To List American Depositary Shares On NASDAQ
MT
2022Relief Therapeutics files registration statement on form F-1 with the U.S. Securities a..
EQ
2022Relief Therapeutics Holding AG has filed an IPO.
CI
2022NRx Pharmaceuticals, Relief Therapeutics Reach Tentative Settlement Over Zyesami Litiga..
MT
2022Relief Therapeutics, NRx Pharmaceuticals Secure Tentative Settlement Over Aviptadil Dis..
MT
2022Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlem..
EQ
2022Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
EQ
2022Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access,..
CI
2022Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Gra..
AQ
2022Acer Therapeutics, Relief Therapeutics Say EU Grants Orphan Drug Designation to ACER-00..
MT
2022RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Co..
CI
2022Relief Therapeutics Partner Acer Gets EU Orphan Drug Designation For Maple Syrup Urine ..
MT
2022Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Gra..
EQ
2022Relief Therapeutics : Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance fo..
PU
2022Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for ..
CI
2022Relief Therapeutics' New Formulation For Lung Disease Drug Shows Clinical Significant I..
MT
2022Relief Therapeutics : Announces Promising Initial Stability Data on a New Formulation of R..
PU
2022Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of ..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Res..
CI
2022Acer Therapeutics : FDA Accepts Resubmitted NDA for ACER-001
DJ
1  2  3  4  5  6  7  8  9Next
Upcoming event on RELIEF THERAPEUTICS HOLDING AG